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A B S T R A C T
Background
Drug resistance in Plasmodium falciparum poses a major threat to malaria control.
Combination antimalarial therapy including artemisinins has been advocated recently to
improve efficacy and limit the spread of resistance, but artemisinins are expensive and
relatively untested in highly endemic areas. We compared artemisinin-based and other
combination therapies in four districts in Uganda with varying transmission intensity.
Methods and Findings
We enrolled 2,160 patients aged 6 mo or greater with uncomplicated falciparum malaria.
Patients were randomized to receive chloroquine (CQ) þ sulfadoxine-pyrimethamine (SP);
amodiaquine (AQ) þ SP; or AQ þ artesunate (AS). Primary endpoints were the 28-d risks of
parasitological failure either unadjusted or adjusted by genotyping to distinguish recrudes-
cence from new infections.
A total of 2,081 patients completed follow-up, of which 1,749 (84%) were under the age of 5
y. The risk of recrudescence after treatment with CQþSP was high, ranging from 22% to 46% at
the four sites. This risk was significantly lower (p, 0.01) after AQþSP or AQþAS (7%–18% and
4%–12%, respectively). Compared to AQ þ SP, AQ þ AS was associated with a lower risk of
recrudescence but a higher risk of new infection. The overall risk of repeat therapy due to any
recurrent infection (recrudescence or new infection) was similar at two sites and significantly
higher for AQþ AS at the two highest transmission sites (risk differences¼ 15% and 16%, p ,
0.003).
Conclusion
AQþAS was the most efficacious regimen for preventing recrudescence, but this benefit was
outweighed by an increased risk of new infection. Considering all recurrent infections, the
efficacy of AQþ SP was at least as efficacious at all sites and superior to AQþAS at the highest
transmission sites. The high endemicity of malaria in Africa may impact on the efficacy of
artemisinin-based combination therapy.
The registration number for this trial is ISRCTN67520427 (http://www.controlled-trials.com/
isrctn/trial/j/0/67520427.html).
PLoS Medicine | www.plosmedicine.org July 2005 | Volume 2 | Issue 7 | e1900654
Open access, freely available online PLoSMEDICINE
Introduction
Malaria remains one of the most serious global health
problems and a leading cause of childhood morbidity and
mortality, especially in Africa [1]. Efforts to control malaria in
Africa have been severely compromised by the emergence of
resistance in Plasmodium falciparum to the inexpensive and
widely used drugs, chloroquine (CQ) and sulfadoxine-pyr-
imethamine (SP) [2,3]. Use of combination antimalarial
therapy, particularly newer regimens containing artemisi-
nin-based compounds, has been widely advocated [4]. How-
ever, concerns regarding the cost and availability of
artemisinin-based combination therapy (ACT) remain, and
limited data comparing ACT with other combination
therapies in Africa are available [5]
In 2000, Uganda replaced CQ with the combination of CQ
þ SP as the recommended first-line treatment for uncompli-
cated malaria, although efficacy data for this regimen were
lacking. To support development of a rational antimalarial
treatment policy, the Uganda Malaria Surveillance Project
was formed as a collaborative effort between the Ugandan
Malaria Control Program, the East African Network for
Monitoring Antimalarial Therapy, and academic researchers
to provide efficacy data on antimalarial therapies from
multiple sites. In addition to providing efficacy data from
diverse locales, this project offers the possibility of evaluating
the impacts of varied malaria endemicities and drug
resistance patterns on responses to antimalarial therapy.
In a recent study from a relatively low-transmission site in
Kampala, Uganda, combinations of amodiaquine (AQ) þ SP
and AQþ artesunate (AS) were found to be significantly more
efficacious than CQ þ SP. Directly comparing the two AQ-
containing regimens over 28 d, AQþSP was associated with a
higher risk of recrudescence after therapy, and AQþAS was
associated with a higher risk of new infections, such that the
overall risk of repeat therapy was similar [6]. Considering all
recurrent infections, the ACT regimen did not offer an
obvious advantage over the much less expensive AQ þ SP
combination. However, this conclusion led to concerns that
results may have been unique to our study site and that the
implications of recrudescent and new infections might be
very different [7]. Here we report the results of randomized
clinical trials comparing CQþ SP, AQþ SP, and AQþ AS at
four additional sites in Uganda, conducted with the aim of
providing data from areas of varying transmission intensity to
help guide antimalarial treatment policy. Furthermore, we
were interested in evaluating the interplay between trans-
mission intensity and the efficacies of different combination
regimens, considering effects both on recrudescences and
new infections after therapy.
Methods
Study Design and Study Sites
We conducted single-blind, randomized clinical trials to
compare the efficacy and safety of three combination
antimalarial regimens at four district health centers, using a
common study protocol. Study sites, selected for geographic
diversity, were: Jinja (periurban, southern Uganda, medium-
high endemicity), Arua (rural, northwest Uganda, very high
endemicity), Apac (rural, central Uganda, very high ende-
micity), and Tororo (rural, southeast Uganda, very high
endemicity) (Figure 1). The level of transmission intensity was
further characterized based on recent estimates of entomo-
logical inoculation rates (the number of infective bites per
person per year): Jinja¼ 7, Arua¼ 393, Tororo¼ 591, Apac¼
1,564 (P. Okello, Uganda Ministry of Health, personal
communication). The study protocol was approved by the
Uganda National Council of Science and Technology and the
institutional review boards of the University of California,
San Francisco and the University of California, Berkeley
(Protocols S1 and S2).
Patients
Consecutive patients presenting to district health centers
between November 2002 and May 2004 with symptoms
suggestive of malaria and a positive-screening thick blood
smear were referred to study physicians. Patients were
enrolled if they fulfilled the following selection criteria: (1)
age 6 mo or greater; (2) history of fever in the last 24 h or
axillary temperature . 37.5 8C; (3) no history of serious side
effects to study medications; (4) no evidence of a concomitant
febrile illness; (5) provision of informed consent; (6) no
history of treatment with an antifolate or AQ during the
previous week; (7) absence of pregnancy-based on history of
last menstrual period; (8) no danger signs or evidence of
severe malaria [8]; and (9) P. falciparum monoinfection with
parasite density 2,000/ll–200,000/ll. Because laboratory re-
Figure 1. Map of Uganda Based on Malaria Endemicity
Very low or no malaria: unstable malaria with varying parasite rates in
children but generally below 5% (altitude above 1,700 m); low: parasite
rates in children below 10% (altitude 1,500–1,700 m); medium to high:
parasite rates in children above 10% and generally below 50%, except for
seasonal peaks (altitude 1,300–1,500 m); very high: parasite rates in
children above 50% (altitude below 1,300 m) (Malaria Control Program,
Uganda Ministry of Health). EIR, entomological inoculation rate.
DOI: 10.1371/journal.pmed.0020190.g001
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sults were generally not available until the following day, a
patient could be excluded after randomization.
Treatment, Randomization, and Blinding
Patients were randomly assigned to receive one of three
oral therapies: CQ (10 mg/kg on days 0 and 1, and 5 mg/kg on
day 2) þ SP (25 mg/kg sulfadoxine and 1.25 mg/kg pyrimeth-
amine as a single dose on day 0); AQ (10 mg/kg on days 0 and
1, and 5 mg/kg on day 2)þ SP; or AQþAS (4 mg/kg on days 0,
1, and 2). Patients in the CQ þ SP and AQ þ SP treatment
arms also received lactose placebo tablets on days 1 and 2.
Randomization codes were computer-generated by an off-
site investigator for two age groups (6–59 mo and 5 y or older)
and provided to a study nurse responsible for treatment
allocation. All other study personnel were blinded to the
treatment assignments, and patients were not informed of
their treatment regimen. Patients were directly observed for
30 min after treatment, and the dose was readministered if
vomiting occurred. Patients who repeatedly vomited their
first dose of study medication were excluded from the study.
Follow-Up Procedures and Classification of Treatment
Outcomes
Following enrollment, patients were asked to return for
follow-up visits on days 1, 2, 3, 7, 14, 21, 28, and any other day
when they felt ill. Blood was obtained by finger prick for thick
blood smears and storage on filter paper on all follow-up days
except day 1. Hemoglobin measurements were repeated on
day 28 or the day of treatment failure.
Treatment outcomes were classified according to 2003
World Health Organization guidelines as early treatment
failure (ETF; danger signs or complicated malaria or failure
to adequately respond to therapy days 0–3), late clinical
failure (LCF; danger signs or complicated malaria or fever
and parasitemia on days 4–28 without previously meeting
criteria for ETF), late parasitological failure (LPF; asympto-
matic parasitemia on day 28 without previously meeting
criteria for ETF or LCF), and adequate clinical and para-
sitological response (ACPR; absence of parasitemia on day 28
without previously meeting criteria for ETF, LCF, or LPF) [8].
Patients classified as treatment failures were treated with
quinine (10 mg/kg three times daily for 7 d); however, their
response to repeat therapy was not assessed. Patients were
excluded after enrollment if any of the following occurred: (1)
use of antimalarial drugs outside of the study protocol; (2)
parasitemia in the presence of a concomitant febrile illness;
(3) withdrawal of consent; (4) loss to follow-up; (5) protocol
violation; and (6) death due to a nonmalaria illness.
Laboratory Procedures
Blood smears were stained with 2% Giemsa for 30 min.
Parasite densities were determined from thick blood smears
by counting the number of asexual parasites per 200 WBCs
(or per 500, if the count was less than 10 parasites/200 WBCs),
assuming a WBC count of 8,000/ll. A smear was considered
negative if no parasites were seen after review of 100 high-
powered fields. Thin blood smears were used to detect
nonfalciparum infections. Hemoglobin measurements were
made using a portable spectrophotometer (HemoCue, Angl-
holm, Sweden). Molecular genotyping techniques were used
to distinguish recrudescence from new infection for all
patients failing therapy after day 3. Briefly, filter paper blood
samples collected on the day of enrollment and the day of
failure were analyzed for polymorphisms in merozoite
surface protein-2 (MSP-2) using nested-PCR as previously
described [9]. Genotyping patterns on the day of repeat
therapy were compared with those at treatment initiation
using GelCompar II software (Applied Maths, St-Martens-
Latem, Belgium). An outcome was defined as recrudescence if
all alleles present at the time of retreatment were present at
the time of treatment initiation, and as a new infection
otherwise.
Statistical Analysis
The study was designed to test the hypothesis that treat-
ment with AQ þ SP or AQ þ AS would change the risk of
recrudescence compared to CQ þ SP at each study site. We
calculated that 176 patients were needed to be enrolled in
each treatment arm at each site for a 0.05 two-sided type I
error with 0.8 power, assuming a risk of recrudescence
adjusted by genotyping of 15% in the CQþ SP group and 5%
in the comparison groups.
Data were double-entered and verified using EpiInfo 6.04
(Centers for Disease Control and Prevention, Atlanta,
Georgia, United States), and analyzed using Stata version
8.0 (Stata Corporation, College Station, Texas, United States).
Efficacy data were evaluated using a per-protocol analysis,
which only included patients with treatment outcomes. Prior
to completion of this study we decided that a per-protocol
analysis would be more appropriate than an intention-to-
treat (ITT) analysis. Our protocol was used to study CQþ SP
versus AQ þ SP at three additional sites prior to the
completion of the studies presented here. During the analysis
of these previous studies we decided that a per-protocol
analysis provided better estimates of the true risk of treat-
ment outcomes than an ITT analysis, as in an ITT analysis one
must assign treatment outcomes to patients who did not
complete the study. In addition, there were so few patients
enrolled who did not complete the study at all our sites that
the comparative results using a per-protocol analysis did not
differ from that using an ITT analysis. Primary efficacy
outcomes included the 28-d risks for all recurrent infection
(ETF, LCF, or LPF), recrudescence (all ETF and any LCF or
LPF categorized as recrudescence based on genotyping
results), and new infections (any LCF or LPF categorized as
new infection based on genotyping results). Risks of recru-
descence and new infection were estimated using the Kaplan-
Meier product limit formula with censoring for the compet-
ing risk (new infections censored when estimating risks of
recrudescence and vice versa). Secondary outcomes included
the risk of recurrent infection unadjusted by genotyping at
day 14, presence of fever on days 1–3, parasitemia on days 2
and 3, change in hemoglobin level between the day of
enrollment and the last day of follow-up, presence of
gametocytes during any follow-up day, and the incidence of
adverse events. Pairwise comparisons of treatment efficacy
were made using risk differences with exact 95% confidence
intervals (CIs). Other categorical variables were compared
using chi-squared or Fisher’s exact test, and continuous
variables were compared using the independent samples t-
test. All reported p-values were two-sided, without adjustment
for multiple testing, and were considered statistically signifi-
cant if less than 0.05.
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Results
Enrollment
Of 2,684 patients who underwent screening, 2,270 were
randomized to treatment, and 2,160 were enrolled in the
studies (Figure 2). Primary efficacy outcomes, unadjusted and
adjusted by genotyping, were available for 96% and 95% of
patients enrolled, respectively.
Baseline Characteristics
Baseline characteristics of the patients across the three
treatment groups were similar at each site (Table 1). Between
the four sites, patients differed in some baseline character-
istics, as expected based on differences in transmission
intensity (Table 1). Patients from Jinja were older, with 39%
age 5 y or older, compared to less than 10% at the other sites
(p , 0.001), consistent with more common presentation of
older individuals with malaria at a lower transmission site.
Patients from Jinja also had higher baseline temperatures (p
, 0.001) and mean hemoglobin levels (p , 0.001) compared
to the other sites. Parasite densities varied significantly across
the sites (p , 0.001 for all pairwise comparisons) and
decreased with increasing entomological inoculation rate
estimates. The proportion of patients with gametocytes
present in pretreatment samples varied considerably (p ,
0.001), ranging from 10% (Jinja and Tororo) to 51% (Apac).
The proportion of patients providing a history of recent CQ
use ranged from 5% (Arua) to 28% (Jinja), with 90% of
patients reporting a partial treatment course (less than three
doses) prior to presentation at the district health centers.
Primary Outcome: Treatment Efficacy
ETFs were uncommon, but significant differences between
the three treatment groups were observed when data from all
sites were combined (CQþ SP¼ 3.4%, AQþ SP¼ 1.0%, AQþ
AS¼ 0.1%; p , 0.04 for all pairwise comparisons). The risk of
recurrent infection (unadjusted by genotyping) at day 14 was
significantly higher for CQ þ SP at all four sites (16%–57%)
compared to AQ þ SP (1%–11%) or AQ þ AS (5%–13%)
(Table 2). The risk of recurrent infection at day 28 was
extremely high for CQ þ SP at all four sites, ranging from
63% to 88% (Table 2). After adjustment by genotyping, the
risk of recrudescence remained very high for CQ þ SP at all
four sites, ranging from 22%–46% (Table 2). Compared to
CQþ SP, the risk of recurrent infection and recrudescence at
day 28 was significantly lower for the AQþSP (28%–59% and
7%–18%, respectively) and AQ þ AS (19%–74% and 4%–
12%, respectively) treatment groups (all ps , 0.05, Table 2).
The most interesting comparisons of treatment efficacy
were seen with AQ þ SP versus AQ þ AS. AQ þ SP was
associated with a higher risk of recrudescence at three sites,
although this reached statistical significance at only one site,
Jinja (risk difference ¼ 9%; 95% CI: 3%–15%; p ¼ 0.009)
Figure 2. Trial Profile
Trial profile stratified by treatment group and site (Jinja, Arua, Tororo, Apac); screened: (693, 625, 718, 648); excluded during initial screening: (122, 74,
157, 61); randomized: CQþSP (179, 184, 174, 196); AQþ SP (196, 185, 192, 197); AQþAS (196, 182, 195, 194); excluded before enrollment: CQþ SP (4, 11,
8, 11); AQþ SP (5, 14, 11, 10); AQþ AS (8, 20, 1, 7); enrolled: CQþ SP (168, 180, 166, 185); AQþ SP (186, 180, 181, 183); AQþ AS (189, 174, 194, 174);
excluded after enrollment: CQþ SP (8, 2, 4, 5); AQþ SP (13, 7, 9, 5); AQþAS (8, 3, 13, 2); completed: CQþ SP (160, 178, 162, 180); AQþ SP (173, 173, 172,
178); AQþAS (181, 171, 181, 172).
DOI: 10.1371/journal.pmed.0020190.g002
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(Figure 3). In contrast, the risk of new infection associated
with AQþ SP and AQþ AS was similar at two sites, and was
significantly higher with AQ þ AS at the two highest
transmission intensity sites, Tororo (risk difference ¼ 21%;
95% CI: 10%–31%; p , 0.001) and Apac (risk difference ¼
15%; 95% CI: 5%–25%; p¼ 0.003) (Figure 3). Overall, the risk
of any recurrent infection (recrudescence or new infection)
was similar at the two lower transmission intensity sites and
significantly higher with AQ þ AS at the two highest
transmission intensity sites; Tororo (risk difference ¼ 15%;
95% CI: 5%–25%; p¼0.005) and Apac (risk difference¼16%;
95% CI: 6%–26%; p ¼ 0.004) (Figure 3).
Although some patients classified as failures had asympto-
matic parasitemia on day 28 (LPF), the majority (67%) were
symptomatic on the day of failure (ETF or LCF). Comparisons
of treatment efficacy (both unadjusted and adjusted by
genotyping) considering only those patients who were
symptomatic on the day of failure were similar to those
above (data not shown).
Comparisons of the characteristics of late clinical and
parasitological failures due to recrudescence versus those due
to new infections are presented in Table 3. Median duration
to failure was shorter with recrudescences compared to new
infections (26 d versus 27 d, p¼ 0.03), although the difference
was marginal, and over 75% of both recrudescences and new
infections occurred after 20 d of follow-up. No differences
between recrudescences and new infections were found with
respect to the proportion of patients who were symptomatic,
the risk of complicated malaria, parasite density, or changes
in hemoglobin. Gametocytes during follow-up were common
with both outcomes, but more common with recrudescences
(51% versus 43%, p ¼ 0.02).
Secondary Outcomes
Treatment with AQþAS was associated with a significantly
lower risk of parasitemia on day 2 at all four sites (2%–9%)
compared to CQ þ SP (37%–74%) or AQ þ SP (33%–58%);
however, this was not consistently associated with clinical
benefit as measured by presence of fever and hemoglobin
level (Table 4). The proportion of patients with temperature
. 37.5 8C on day 2 was significantly lower in the AQ þ AS
group compared to CQ þ SP at two sites, but there were no
significant differences compared to the AQþSP group (Table
4). Similar results were seen with temperature on days 1 and 3
and when considering subjective fever (data not shown).
Increase in hemoglobin during follow-up was greatest in the
AQþ SP group at all sites, reaching statistical significance at
Table 1. Baseline Characteristics of Patients Completing the
Study
Characteristic Location Treatment Group
CQ þ SP AQ þ SP AQ þ AS
Percent female Jinja 63% 55% 52%
Arua 53% 47% 45%
Tororo 54% 51% 49%
Apac 47% 44% 49%
Median age in years
(% under 5)
Jinja 4.0 (58%) 3.5 (63%) 3.5 (60%)
Arua 1.4 (93%) 1.5 (93%) 1.6 (94%)
Tororo 1.3 (91%) 1.2 (93%) 1.3 (93%)
Apac 1.9 (89%) 1.8 (90%) 1.7 (91%)
Mean temperature 8C (SD) Jinja 37.9 (1.0) 37.9 (1.1) 37.9 (1.1)
Arua 37.4 (1.1) 37.2 (0.9) 37.3 (1.0)
Tororo 37.3 (0.8) 37.5 (1.0) 37.5 (1.0)
Apac 37.1 (0.8) 37.1 (0.9) 37.0 (0.8)
Parasite density per lla Jinja 34,322 37,256 34,077
Arua 21,484 25,400 24,316
Tororo 19,328 18,534 17,589
Apac 12,558 11,877 10,599
Mean hemoglobin g/dl (SD)b Jinja 10.8 (2.3) 10.4 (2.3) 10.7 (2.2)
Arua 9.2 (1.7) 9.2 (1.7) 9.4 (1.7)
Tororo 8.9 (2.1) 8.9 (1.8) 9.1 (1.9)
Apac 9.2 (1.9) 9.4 (1.9) 9.2 (1.9)
Proportion with gametocytes
on day 0
Jinja 8% 13% 8%
Arua 36% 25% 30%
Tororo 15% 6% 12%
Apac 50% 51% 52%
aGeometric mean
bSI conversion: 1 g/dl ¼ 10 g/l.
DOI: 10.1371/journal.pmed.0020190.t001
Table 2. Primary Treatment Efficacy Outcomes
Location Risk Treatment Group
CQ þ SP AQ þ SP AQ þ AS
Jinja n ¼ 160 n ¼ 173 n ¼ 181
Risk of recurrent infection
day 14a (unadjusted)b,c
32% 4% 5%
Risk of recurrent infection
day 28a (unadjusted*)b,c
63% 28% 19%
Risk of recrudescence
day 28d (adjusted) b,c,e
40% 13% 4%
Risk of new infection
day 28d (adjusted) b,c
34% 16% 14%
Arua n ¼ 178 n ¼ 173 n ¼ 171
Risk of recurrent infection
day 14a (unadjusted)b,c
57% 11% 13%
Risk of recurrent infection
day 28a (unadjusted)b,c
86% 53% 51%
Risk of recrudescence
day 28d (adjusted)b,c
46% 14% 9%
Risk of new infection
day 28d (adjusted)b,c
67% 43% 44%
Tororo n ¼ 162 n ¼ 172 n ¼ 181
Risk of recurrent infection
day 14a (unadjusted)b,c
40% 4% 8%
Risk of recurrent infection
day 28a (unadjusted)b,c,e
88% 59% 74%
Risk of recrudescence day
28d (adjusted)b,c
34% 18% 12%
Risk of new infection day
28d (adjusted)c,e
76% 47% 68%
Apac n ¼ 180 n ¼ 178 n ¼ 172
Risk of recurrent infection
day 14a (unadjusted)b,c,e
16% 1% 5%
Risk of recurrent infection
day 28a (unadjusted)b,c,e
66% 36% 52%
Risk of recrudescence
day 28d (adjusted)b,c
22% 7% 10%
Risk of new infection
day 28d (adjusted)c,e
49% 29% 44%
aSimple proportion of patients with ETF, LCF, or LPF after 14 and 28 d of follow-up.
bCQ þ SP versus AQ þ SP, p , 0.05.
cCQ þ SP versus AQ þ AS, p , 0.05.
dKaplan-Meier product limit formula (new infection censored when estimating risk of recrudescence and
recrudescences censored when estimating risk of new infection).
eAQ þ SP versus AQ þ AS, p , 0.05.
DOI: 10.1371/journal.pmed.0020190.t002
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three sites when compared to CQþ SP and at one site when
compared to AQ þ AS (Table 4). The proportion of patients
with gametocytes during follow-up was lowest in the AQþAS
group at all sites, reaching statistical significance at two sites
when compared to CQ þ SP and at one site when compared
to AQ þ SP (Table 4). When restricting the analysis to only
those patients with no gametocytes on day 0, a similar trend
was found, favoring AQ þ AS, with statistical significance
reached at all four sites when compared to CQ þ SP and at
two sites when compared to AQ þ SP (Table 4).
Safety and Tolerability
Among 2,160 patients enrolled in the studies, 20 serious
adverse events were reported in 16 patients (four CQ þ SP,
eight AQþSP, four AQþAS, p¼0.40). Serious adverse events
included anemia (two AQ þ SP, one AQ þ AS), convulsion
(one CQþ SP, two AQþ SP, one AQþAS), dehydration (one
AQþAS), edema (one AQþ SP), malnutrition (one CQþ SP),
mental status change (two AQ þ SP), respiratory illness (one
CQ þ SP, two AQ þ SP, one AQ þ AS), vomiting (one CQ þ
SP), and weakness (one AQ þ SP). One patient died of
suspected severe malnutrition and one patient died of
congestive heart failure due to a presumed congenital heart
defect (both patients had received AQ þ SP). All serious
adverse events were deemed to be unlikely (ten events) or
possibly (ten events) related to the study medications.
Discussion
Antimalarial drug resistance is one of the greatest threats
to malaria control in Africa [10]. In response to widespread
resistance to CQ and SP, use of combination antimalarial
therapy, particularly ACT, has been strongly advocated [11].
This study compared the efficacy of three different combi-
nation therapies, CQþ SP, currently the recommended first-
line regimen in Uganda; AQ þ SP, an inexpensive regimen
that has proven to be efficacious in recent studies; and AQþ
AS, an ACT regimen. More important, evaluations were made
across differing levels of transmission intensity, allowing us to
assess the impact of endemicity on treatment responses. We
found that CQþ SP was highly ineffective. Indeed, data from
various parts of Uganda have shown that the pfcrt K76T
mutation primarily responsible for CQ resistance is virtually
ubiquitous [12,13] and that the efficacy of CQþ SP is similar
to that of SP alone [14]. Replacing CQ with AQ in
combination with SP greatly reduced the risk of recrudes-
cence and prevented new infections, a benefit which was most
evident at the two highest transmission sites. The prevention
of new infections by AQ þ SP is likely due to the long
elimination half-lives of both drugs [15,16]. Compared to AQ
þ SP, treatment with AQþAS was generally associated with a
lower risk of recrudescence but a higher risk of new infection
within the month after therapy. This is likely due to the fact
that AS is rapidly eliminated, leaving only AQ to provide
Figure 3. Comparison of AQ þ SP versus AQ þ AS
Risk differences and 95% CIs for recrudescence (adjusted by genotyping), new infections (adjusted by genotyping), and any recurrent infection
(unadjusted, recrudescence or new infection) at day 28.
DOI: 10.1371/journal.pmed.0020190.g003
Table 3. Comparison of Late Clinical and Parasitological Failures due to Recrudescence versus New Infection
Failure Characteristics Recrudescence (n ¼ 291) New Infection (n ¼ 822) p-Value
Median day of failure (IQR) 26 (21–28) 27 (21–28) 0.03
Symptomatic on day of failure (LCF), no. (%) 193 (66%) 550 (67%) 0.86
Complicated malariaa on day of failure, no. (%) 0 1 (0.1%) 1.0
Geometric mean parasite density per ll 6,747 7,498 0.49
Mean increase in hemoglobin g/dl (SD) 1.01 (1.68) 1.14 (1.64) 0.28
Gametocytes present on day 0, no. (%) 78 (27%) 227 (28%) 0.80
Gametocytes present on any follow-up day, no. (%) 149 (51%) 353 (43%) 0.02
aSevere malaria or danger signs.
IQR, interquartile range.
DOI: 10.1371/journal.pmed.0020190.t003
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posttreatment prophylaxis. When comparing AQþAS to AQ
þ SP, the overall risks of recurrent infection were similar at
two study sites and significantly higher for AQþAS at the two
highest transmission sites.
Differences in treatment efficacies between our study sites
could not be compared formally, as patient populations
differed between sites. Nonetheless, wide differences in
efficacies between sites were seen. These differences may
have been due both to variations in endemicity (and there-
fore antimalarial immunity) and to varied drug resistance
patterns. Varied endemicity likely played an important role,
as suggested by marked differences in baseline characteristics
between the study populations. Considering varied drug
resistance patterns, preliminary data analyzing parasites from
the four sites suggest that the prevalences of mutations
known to mediate resistance to CQ and SP were similar
(unpublished data). Thus, the major factor mediating differ-
ences in outcomes between study sites appears to be differ-
ences in the antimalarial immunity of study populations.
Antimalarial drug-efficacy studies that limit follow-up to 14
d or less may significantly underestimate the risk of
recrudescence [17]. Our study shows that this underestima-
tion is particularly problematic in regions with very high
malarial endemicity. Overall, only 21% of recrudescences
occurred within the first 2 wk of the 4-wk follow-up period,
and this proportion decreased to 14% at the highest
transmission site. Thus, in highly endemic areas recrudes-
cence may be delayed, presumably due to the contribution of
host immunity on initial parasite clearance, and this delay
appears to increase with increasing transmission intensity
[17]. Additionally, the risk of new infections can be
substantial in highly endemic areas. Indeed, in our study
72% of all recurrent infections were due to new infections,
and with our two most efficacious regimens (AQþSP and AQ
þ AS) this proportion was 80%. Although comparisons of
antimalarial drug efficacy generally do not consider the
relative impact on the risk of new infections, this factor can
play a large role in treatment outcomes, especially in high-
transmission areas such as Africa. Our identification of
frequent new infections emphasizes the importance of other
malaria control measures, such as the use of bed nets, vector
reduction, and possibly intermittent presumptive therapy, as
ways of reducing the risk of new infections and maximizing
the impact of therapy.
Follow-up in this study was limited to 28 d. In a previous
longitudinal study of SP alone or in combination with AQ or
AS from Uganda, 72% of recrudescences occurred within 28
d and 81% within 42 d [18]. Thus, the overall risk of
recrudescence in this study was likely underestimated.
Similarly, we may have underestimated the impacts of the
different therapies on risks of new infection. These limi-
tations will be present in any study with distinct endpoints for
efficacy assessment, but it is generally agreed that 28-d
outcomes offer a reasonable comparative assessment of
antimalarial therapies [8]. However, the best comparisons of
the impacts of different therapies on the overall risk of repeat
therapy can only be made using a longitudinal study design
with extended follow-up covering multiple episodes of
malaria, as we described previously [18].
We suggest that antimalarial therapies be judged not only
by their impact on the risk of recrudescence, but also by their
impact on the risk of new infections after therapy [6].
However, it has been argued that the consequences of
recrudescence and new infection are not equal and that
Table 4. Secondary Treatment Outcomes
Patient Condition Location Treatment Group
CQ þ SP AQ þ SP AQ þ AS
Proportion with parasitemia on day 2 Jinjaa,b 58% 57% 9%
Aruaa,b,c 74% 58% 5%
Tororoa,b 37% 33% 6%
Apaca,b 45% 37% 2%
Proportion with temperature . 37.5 8C on day 2 Jinjaa 5.0% 2.3% 0.6%
Aruaa,c 7.3% 1.7% 0.6%
Tororo 5.6% 1.7% 2.8%
Apac 1.7% 1.1% 1.2%
Mean increase in hemoglobin g/dl (SD) Jinjaa,c 0.44 (1.75) 1.15 (1.93) 0.95 (1.91)
Aruaa,c 0.67 (1.54) 1.44 (1.60) 1.44 (1.67)
Tororob,c 0.99 (1.58) 1.58 (1.55) 1.14 (1.48)
Apac 1.56 (1.55) 1.77 (1.79) 1.76 (1.55)
Proportion with gametocytes during follow-up Jinja 34% 32% 25%
Aruaa,b 55% 49% 36%
Tororoa,c 36% 22% 18%
Apac 70% 69% 60%
Proportion with newly emerging gametocytesd Jinjaa 29% 22% 20%
Aruaa,b 41% 35% 18%
Tororo,a,b 28% 20% 11%
Apaca 52% 46% 33%
aCQ þ SP versus AQ þ AS, p , 0.05
bAQ þ SP versus AQ þ AS, p , 0.05
cCQ þ SP versus AQ þ SP, p , 0.05
dPatients with gametocytes on day 0 excluded from the analysis.
DOI: 10.1371/journal.pmed.0020190.t004
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patients who have recrudescence face a greater risk of
progression to complicated malaria and death [7]. Our data
do not support this contention. In our study, the risk of ETF
was remarkably low (,2%), and only four of 2,081 patients
progressed to severe malaria or danger signs requiring
therapy with intravenous quinine during the first 3 d of
follow-up. Among 1,133 failures identified 4–28 d after
therapy, 760 (67%) patients were symptomatic (LCFs), and
clinical differences between recrudescence and new infection
were not apparent. The only episode of severe malaria/danger
signs to occur after day 3 was caused by a new infection. Thus,
we found no support for the argument that the clinical
consequences of recrudescence after treatment are different
from those of a new infection during our 28 d follow-up
period. It has also been argued that recrudescences are more
difficult to treat than new infections. We could not address
this issue in this study as patients were not assessed following
repeat therapy. However, treatment of recrudescent infec-
tions was compared to initial treatment in a previous
longitudinal study. Although the treatment of recrudescent
infections with SP was associated with a higher rate of
treatment failure, interestingly, treatment with SP þ AS was
associated with a lower rate of treatment failure [19].
Additional studies with longer follow-up, covering repeated
episodes of malaria, are needed to more fully evaluate the
treatment implications of recrudescent infections.
The classification of recrudescence and new infection
depends on the genotyping methods used. In our study we
used a highly specific definition of recrudescence that required
all alleles present at the time of retreatment be present at the
time of treatment initiation. As recurrent infections contain-
ing both new alleles and alleles present at the treatment
initiation were classified as new infections, we may have
underestimated the true risk of recrudescence. Defining
recrudescence as having any allele at the time of retreatment
present at the time of treatment initiation increased our point
estimates of the risk of recrudescence. However, using this
more sensitive (but less specific) definition of recrudescence
did not have a significant impact on comparative efficacies.
Indeed, we suggest that the most useful comparisons of the
clinical consequences of different treatments should be based
on treatment outcome results unadjusted by genotyping,
including all retreatments for clinical illness.
Artemisinin derivatives are highly attractive antimalarials
because they act rapidly, are well tolerated, and are currently
not limited by resistance [3]. However, artemisinin mono-
therapy is associated with a high risk of recrudescence,
necessitating use of artemisinins in combination with other
antimalarials to achieve maximum efficacy [20]. In Thailand,
the combination of ASþmefloquine has been associated with
sustained cure rates over 95% and a decreased incidence of
malaria [21,22]. The coformulated ACT, artemether-lumefan-
trine, has been shown to be highly efficacious in relatively low
endemicity sites in Southeast Asia [23–25]. Published evi-
dence for the effectiveness of ACT in highly endemic areas of
Africa remains limited. The combination of CQ þ AS was
associated with a 47%–93% risk of treatment failure
(unadjusted by genotyping) after 28 d in three West African
countries [26]. SP þ AS was associated with a higher risk of
treatment failure (unadjusted and adjusted by genotyping)
compared to AQ þ SP in Uganda and Rwanda [18,27]. AQ þ
AS was associated with a lower risk of recrudescence but a
similar risk of overall treatment failure when compared to
AQþ SP at a site with relatively low-transmission intensity in
Uganda [6].
Although ACT is clearly better than standard monothera-
pies, the somewhat disappointing results of ACT in Africa
probably relate to the high endemicity of malaria and the
inclusion of inadequate partner drugs with the artemisinins.
Considering endemicity, patients with symptomatic malaria
from highly endemic areas such as Africa generally have
higher pretreatment parasite densities compared to patients
from lower endemic areas such as Southeast Asia[3], and
higher pretreatment parasite densities have been associated
with a higher risk of recrudescence after treatment with AS
[28]. Additionally, the increased risk of new infections in
highly endemic areas may contribute greatly to treatment
outcome. These factors suggest that in Africa, more so than
other areas, it is critical that artemisinins be combined with
other highly effective drugs. However, whether partner drug
should be short- or long-acting remains unclear. Long-acting
partner drugs offer an extended prophylactic effect; however,
they may encourage the selection of drug resistance.
Considering the efficacy of ACTs, initial studies in Africa
combining AS with available drugs (CQ, SP, and AQ), were
relatively disappointing in areas where the efficacy of the
partner drugs was likely limited by resistance, as was seen in
this study [18,26,27]. ACT regimens with more effective
partner drugs (e.g., artemether-lumefantrine and/or dihy-
droartemisinin-piperaquine) will likely show improved effi-
cacy [4].
Despite the limitations noted, ACT and other antimalarial
combination therapies offer great hope for Africa. However,
the ideal combination regimens remain uncertain [4]. As
African countries rapidly move toward replacement of
ineffective monotherapies with combinations regimens, it is
essential that controlled trials be conducted to compare
efficacy, ideally considering the importance of varied trans-
mission intensity. Studies with extended follow-up and
longitudinal designs will provide the most useful compar-
isons, as different therapies may impact very differently on
long-term outcomes. Based on the results of this study and
others, Uganda has recently opted to replace CQ þ SP with
artemether-lumefantrine, joining many other African coun-
tries in choosing an ACT as first-line therapy. However, cost
and availability of ACTs remain major concerns, and it
appears that the sudden increase in demand for artemisinins
may exacerbate these problems, at least in the short-term [5].
The inexpensive and widely available combination AQ þ SP
may still be appropriate for the treatment of uncomplicated
malaria in areas where resistance to the drugs is relatively
uncommon, in situations where ACT may not be feasible (e.g.,
such as the treatment of unconfirmed cases of malaria outside
of the formal health sector), and, in the short term, while
adequate supplies of ACT are not yet available in Africa.
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Patient Summary
Background As resistance to current malarial regimens grows, it is
increasingly important to find new combinations of drugs that will not
only treat an ongoing infection, but will also prevent recurrence of the
malaria (either a new infection or reappearance of the treated infection).
One type of drug that is being assessed for preventing recurrence is
based on artemisinin, which was originally derived from a plant, sweet
wormwood. However, this drug is more expensive than older drugs
What Did the Authors Do? They did four randomized clinical trials in
Africa at the same time; two in areas where malaria occurs very
frequently and two where it is less frequent. They compared a
combination of artemisinin with two other combinations of older drugs
and looked to see how well the treatments worked on the present
infection, on preventing recurrences, and on whether there were any
serious adverse events.
They found that the combination including artemisinin worked the best
at treating current infections. However, patients given the artemisinin-
based treatment were overall more likely to get new infections. Where
malaria was very common, people treated with the artemisinin-based
combination were more likely to get recurrent infections overall.
What Do These Findings Mean? Although the artemisinin-based
treatment worked very well on present infections, for recurrent
infections it did not perform better than, and was considerably more
expensive than, an older combination of drugs. Artemisinin-based
treatment should not automatically be assumed the best treatment for
uncomplicated malaria in Africa.
Where Can I Get More Information? The World Health Organization
has a Web site on Africa with links to malaria control:
http://www.afro.who.int/
The United Kingdom Department for International Development has
information on malaria control in Africa:
http://www.lshtm.ac.uk/dfid/malaria/
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